Deal Snapshot
UK Biotech MiroBio Agrees to USD 405m Gilead Sciences Buyout
Friday 05 August 2022

UK-based biotechnology company MiroBio Ltd has entered into a definitive agreement with US-based Gilead Sciences (NASDAQ: GILD), Inc. to be acquired for approximately USD 405m in cash, subject to customary adjustments, the firm said.

MiroBio is focused on restoring immune balance with agonists targeting immune inhibitory receptors. MiroBio was spun out of the University of Oxford in 2019 to develop a new class of medicines, called immune checkpoint agonists, to treat autoimmune diseases by restoring balance to the immune system.

Date Published: 05/08/2022